This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / BioArctic and Eisai Present...
Tech Medical conference

BioArctic and Eisai Present Lecanemab Data at AD/PD 2026

Analysis based on 14 articles · First reported Mar 11, 2026 · Last updated Mar 11, 2026

Sentiment
60
Attention
4
Articles
14
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The presentations of new data on Lecanemab by BioArctic and Eisai at the AD/PD 2026 conference are expected to reinforce confidence in the drug's efficacy and safety, potentially leading to increased adoption and positive stock performance for both BioArctic and Eisai. Continued regulatory approvals and expanded market access for Lecanemab in key regions like China, Japan, and the US further solidify its market position and revenue potential.

Biotechnology Pharmaceuticals Healthcare
Event Summary

BioArctic and its partner Eisai are set to present the latest findings on lecanemab at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen. Eisai will focus on real-world efficacy and safety data, along with four-year data from the Clarity AD Open-Label Extension trial for lecanemab. BioArctic's co-founder, Professor Lars Lannfelt, will deliver an oral presentation on lecanemab's mechanisms of action, and BioArctic will also present a poster on exidavnemab for Parkinson's disease. Lecanemab, developed through a collaboration between BioArctic and Eisai, is approved in 53 countries and is under regulatory review in 6 others. Recent developments include the submission of a subcutaneous formulation application in Japan, inclusion in China's 'Commercial Insurance Innovative Drug List', and Priority Review by the US FDA for a subcutaneous starting dose of Leqembi Iqlik.

Key Actions
90 BioArctic will present latest findings on lecanemab and exidavnemab
90 Eisai will present latest findings on lecanemab and host a symposium
75 United States===Food and Drug Administration granted Priority Review for supplemental Biologics License Application Eisai
70 Eisai submitted new drug application for subcutaneous formulation of Lecanemab Japan
Entities Involved
stock
BioArctic
BioArctic, as the inventor of lecanemab and developer of exidavnemab, will present new data at the AD/PD 2026 conference, highlighting its ongoing research and development in neurodegenerative diseases. The company stands to benefit from the continued success and expansion of lecanemab's market reach.
Importance 90 Sentiment 70
stock
Eisai
Eisai, BioArctic's partner, will present extensive data on lecanemab's real-world efficacy and safety, as well as four-year data from the Clarity AD Open-Label Extension trial. Eisai is responsible for the global commercialization of lecanemab, and positive data presentations could further boost its market position.
Importance 90 Sentiment 70
per
Lars Lannfelt
Professor Lars Lannfelt, co-founder of BioArctic, will present on lecanemab's mechanisms of action, underscoring his foundational work in Alzheimer's disease research and the development of lecanemab.
Importance 70 Sentiment 60
stock
Biogen
Biogen is involved in a joint development and commercialization agreement for lecanemab with Eisai, and also participates in the AHEAD 3-45 clinical study. While not a primary presenter at this conference, its association with lecanemab is noted.
Importance 30 Sentiment 50
govactor
United States===Food and Drug Administration
The US FDA granted Priority Review for Eisai's supplemental Biologics License Application for a subcutaneous starting dose of Leqembi Iqlik, indicating regulatory progress for the drug in the United States.
Importance 20 Sentiment 0
govactor
China===National Healthcare Security Administration
The NHSA of China included Leqembi in its 'Commercial Insurance Innovative Drug List', which is a positive development for the drug's market access in China.
Importance 20 Sentiment 0
cnt
Japan
Japan is one of the countries where Leqembi is approved for maintenance dosing and where a new drug application for its subcutaneous formulation was submitted.
Importance 10 Sentiment 0
+ 3 more entities View on Dashboard
Relationships
BioArctic related ↔ Eisai
Lars Lannfelt related ↔ BioArctic
Eisai related ↔ Biogen
Lars Lannfelt related ↔ Eisai
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.